OS Therapies Incorporated Common Stock (OSTX)
Stock · AMEX · Health Care
$1.31as of 10/16/2026
Price chart
Active signals
OSTX Signal Track Record
How signals performed across all stocks →What OSTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 17 | -7.2% | 35% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -0.5% | 44% | August 20, 2026 |
| Bollinger Band BreakdownActive now | 6 | +8.9% | 67% | October 6, 2026 |
| Bollinger Band Breakout | 7 | -11.0% | 14% | September 3, 2026 |
| Any 20-session window (baseline) | -2.2% | 45% |
Computed by MarketWall from daily closing prices since May 19, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- ostherapies.com/
Fundamentals
- 1-day range
- $1.37$1.43
- Market cap
- $74.23M
- P/E (trailing)
- —
- P/E (forward)
- 4.04
- EPS (trailing)
- $-1.07
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 577.0K
Forecasts
4 analyst ratings
OS Therapies Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- OSTXOS Therapies Incorporated Common Stock$1.32▼ 6.38%Market cap $74.23MP/E —$1.15$2.25
- TLPHTalphera Inc. Common Stock$1.08▲ 0.93%Market cap $74.22MP/E —$0.6866$1.57
- ACETAdicet Bio Inc. Common Stock$4.57▼ 11.09%Market cap $74.13MP/E —$4.8$17.04
- SPROSpero Therapeutics Inc. Common Stock$1.1▼ 2.65%Market cap $73.53MP/E 8.91$1.08$3.08
- NMADNomad Power Solutions Inc. Common Stock$3.88▼ 5.13%Market cap $75.50MP/E —$3.12$7.7
- GANXGain Therapeutics Inc. Common Stock$1.26▼ 5.26%Market cap $75.92MP/E —$1.3$4.34
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OSTX OS Therapies Incorporated Common Stock | $74.23M | — | $1.32 | ▼ 6.38% | $1.15$2.25 |
| TLPH Talphera Inc. Common Stock | $74.22M | — | $1.08 | ▲ 0.93% | $0.6866$1.57 |
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $4.57 | ▼ 11.09% | $4.8$17.04 |
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 8.91 | $1.1 | ▼ 2.65% | $1.08$3.08 |
| NMAD Nomad Power Solutions Inc. Common Stock | $75.50M | — | $3.88 | ▼ 5.13% | $3.12$7.7 |
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.26 | ▼ 5.26% | $1.3$4.34 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Rubenstein Public Relations Named Agency of Record for OS TherapiesYahoo · 10/8/2026
- OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine OsteosarcomaYahoo · 10/7/2026
- OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine OsteosarcomaBenzinga · 10/7/2026
- OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer TreatmentBenzinga · 10/6/2026
- OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma TrialYahoo · 10/6/2026
- OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical ControlBenzinga · 10/6/2026
- OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial OfficerYahoo · 10/1/2026
- OS Therapies Appoints Frank Knuettel II As CFOBenzinga · 10/1/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 2.76M
- Total value held
- $3.84M
- Institutional holders
- 27
- Unknown469.5K
- Unknown448.7K
- Unknown400.0K
- Unknown348.7K
- Unknown280.0K
- Unknown245.4K
- Unknown91.2K
- Unknown66.1K
- Unknown64.8K
- Unknown62.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
OSTX: WHO Approves 'Herlystic' Brand Name for OST-HER2
The World Health Organization has approved the brand name Herlystic for OS Therapies' OST‑HER2 product, daznelimgene lisbac. This regulatory approval removes a naming barrier and could aid the therapy's path toward market availability. The stock is currently trading near its $1.58 support level after several touches.
OSTX: WHO Approves 'Herlystic' Brand Name for OST-HER2. The World Health Organization has approved the brand name Herlystic for OS Therapies' OST‑HER2 product, daznelimgene lisbac. This regulatory approval removes a naming barrier and could aid the therapy's path toward market availability. The stock is currently trading near its $1.58 support level after several touches.